Thursday, 15 October 2026European Markets

BOIRON And VETOQUINOL Have A High Dividend Yield And Return On Equity In The Drug Manufacturers—Specialty & Generic Industry.

Loading stream...

(vianews) - boiron (boi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the drug manufacturers—specialty & generic industry.

financial asset price forward dividend yield return on equity
boiron (boi.pa) €50.50 2.2% 8.13%
vetoquinol (veto.pa) €90.30 0.91% 10.37%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. boiron (boi.pa)

2.2% forward dividend yield and 8.13% return on equity

boiron sa manufactures and sells homeopathic medicines in france, rest of europe, north america, and internationally. the company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. it also provides homeopathic specialties comprising oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; stodal and stodaline for treating coughs; arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; camilia for the treatment of teething problems for babies; sédatif pc to treat anxiety and emotional, and minor sleep disorders; coryzalia for the treatment of cold symptoms and rhinitis; homéoptic to treat eye discomfort and irritation due to various causes for adults and children; homéovox for vocal disorders; homéoplasmine for treating irritated skin and redness; varésol to treat symptoms of chickenpox; and arnicare arthritis for use in the treatment of benign trauma pain. in addition, it offers dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; covid self-tests and rapid antigenic tests; labiameo, that used to treat outbreaks of localized cold sores; and convameo to treat physical and mental asthenia. the company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. boiron sa was founded in 1932 and is headquartered in messimy, france.

earnings per share

as for profitability, boiron has a trailing twelve months eps of €2.89.

pe ratio

boiron has a trailing twelve months price to earnings ratio of 17.47. meaning, the purchaser of the share is investing €17.47 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.13%.

dividend yield

as claimed by morningstar, inc., the next dividend payment is on jun 1, 2023, the estimated forward annual dividend rate is 1.1 and the estimated forward annual dividend yield is 2.2%.

more news about boiron.

2. vetoquinol (veto.pa)

0.91% forward dividend yield and 10.37% return on equity

vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.

earnings per share

as for profitability, vetoquinol has a trailing twelve months eps of €4.06.

pe ratio

vetoquinol has a trailing twelve months price to earnings ratio of 22.24. meaning, the purchaser of the share is investing €22.24 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.37%.

more news about vetoquinol.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com